

Dear FEMSelect Shareholders,

FEMSelect Ltd. has been dedicated to transforming the treatment of prolapse for both women and urogynecology through our minimally invasive technology, EnPlace®. With your continued support and confidence in our vision, we have achieved significant milestones, over 3,000 women treated to date, over 100 US hospitals with Value Analysis (VAC) approval 40% growth in YOY sales. As was shared in an email on March 21st, we are seeking additional investment in the form of a convertible note to fuel significant commercialization growth and provide working capital to bridge to break-even while continuing efforts to align with effective Strategic Partners. This Bridge Round is essential for us to continue to prove out the commercial value of EnPlace and to do it quickly to enable us to focus on the business and, at the same time, advance discussions that will showcase our traction and attract the exit we all want to achieve. We will hire additional reps, focus on clinicians who are motivated to build their practice and increase their own revenue from the OR and generate patient referrals to top users.

Many of those who have already committed to the Bridge have requested that we raise more than \$2.5M so that have enough breathing room to get done what needs to be done to achieve an Exit. For that reason, the Note attached reflects a sum of up to \$4.5M so that we do not need to start from scratch should we over-subscribe. At the moment, we have close to \$2M in commitments and are working toward a 1st close by May 4th.

In order to move forward with the Note, we have attached is a Notice of a Meeting of Shareholders requesting your vote. We have several other items that need Shareholder Approval so we have added them to this agenda although they are unrelated to the closing of the Note. The Meeting covers the following subjects:

1. Approval of the proposed loan pursuant to the Note Purchase Agreement and related transaction documents, and the changes necessary to the Articles of Association and capital structure for that Note and warrants.
2. Adoption of a New Share Option Plan—the previous ESOP plan expired and the Resolution here is simply a transfer from the old plan to the new plan. The aggregate number of shares reserved for grants under both the old plan and the new plan has remained the same.
3. Approval of a new Directors & Officers Liability Insurance Policy
4. Receipt of the 2022 Audited Financial Statements and approval of the appointment of KPMG Israel as FEMSelect's auditors for the coming year

The Meeting will take place via Zoom on Tuesday, April 30, 2024 at 10amEST. If you would like to attend via Zoom, please request a link via reply email.

If you are unable or do not wish to join the meeting, I kindly ask that you sign the proxy attached and send it back to me as soon as possible.

Thank you in advance for your support,

Debbie

Debbie Garner

Co-CEO

FEMSelect Ltd.

Tel US: +1-215-940-8178

Tel Israel: +972-54-945-6260

Email: debbie@femselect.com

Notice and Proxy for Shareholders Meeting 2024.04.19:

<https://app.box.com/s/nabyvkc82btrqoa7ypw53oo9qx24ozcs>

Proxy 2024.04.19: <https://app.box.com/s/iffyhid0mjymnbbszhw97nbepfkw099a>